Free Trial
NYSE:WST

West Pharmaceutical Services Q1 2025 Earnings Report

West Pharmaceutical Services logo
$209.28 -3.22 (-1.52%)
As of 03:58 PM Eastern

West Pharmaceutical Services EPS Results

Actual EPS
N/A
Consensus EPS
$1.30
Beat/Miss
N/A
One Year Ago EPS
N/A

West Pharmaceutical Services Revenue Results

Actual Revenue
N/A
Expected Revenue
$685.24 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

West Pharmaceutical Services Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, April 24, 2025
Conference Call Time
9:00AM ET

Conference Call Resources

Remove Ads

West Pharmaceutical Services Earnings Headlines

West Pharmaceutical price target lowered to $280 from $285 at BofA
What is Zacks Research's Estimate for WST Q4 Earnings?
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Zacks Research Brokers Reduce Earnings Estimates for WST
See More West Pharmaceutical Services Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like West Pharmaceutical Services? Sign up for Earnings360's daily newsletter to receive timely earnings updates on West Pharmaceutical Services and other key companies, straight to your email.

About West Pharmaceutical Services

West Pharmaceutical Services (NYSE:WST) designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

View West Pharmaceutical Services Profile

More Earnings Resources from MarketBeat